Infervision

Deep learning image analysis is the whole company across an unusually wide product line: InferRead covering lung CT, chest radiography, coronary CTA, and target reconstruction, InferOperate covering surgical planning for thorax, liver, and urology, and InferCare RECIST for standardized tumour assessment. No scanner or hardware of its own. The breadth is algorithmic breadth rather than a platform business wrapped around models.

Cleared to support CONCURRENT reading, meaning output is available alongside the radiologist's initial interpretation rather than after it. That is the same design choice as Riverain and the opposite of Ibex's second-read sequencing, and it carries the same tradeoff: faster workflow, greater exposure to automation bias. An independent reviewer characterised the tool as a lung nodule spell-checker, which is a fair description of the intended relationship, the human reads and the algorithm catches misses. The surgical planning products sit further from autonomy still, producing plans a surgeon evaluates.

Capability is described concretely, including automated lung segmentation, nodule identification and labelling by type, detection down to 4 mm, and automated lung density analysis, and the regulatory scope of each clearance is stated. What is not published is performance data: no sensitivity, specificity, reader study results, or per-nodule-type accuracy were located for any product in the line. For a vendor claiming detection at 4 mm, where false positive rates rise sharply, the absence of published performance is the material gap.

Deployment scale is substantial and long running, reported at more than 380 hospitals and imaging centres globally processing over 55,000 cases daily, with five years of international clinical use cited at the time of first FDA clearance and a named US partnership with SimonMed, one of the largest outpatient imaging providers. Real world tuberculosis screening deployments in Kyrgyzstan and Zimbabwe, including UN procurement for Eastern Europe and Central Asia, demonstrate the product functions in low resource settings. What is missing is peer reviewed validation: no published reader study, diagnostic accuracy paper, or outcome evidence specific to these products was located, which is a notable gap given the deployment volume. Scale of use is not evidence of benefit.

No specific PHI handling or data governance framework was located. For a China headquartered vendor processing imaging for US and European health systems, data handling and cross border transfer terms are a live procurement question that the public materials do not address.

No HIPAA or BAA commitment was located, despite US operations and a named US imaging partnership. A US buyer should establish business associate terms and confirm processing location explicitly.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

The broadest multi jurisdiction footprint of any vendor in this index's imaging lane, spanning US FDA, European CE, UK UKCA, Japan PMDA, and China NMPA. US clearances include InferRead Lung CT.AI first cleared in 2020, a further clearance in May 2025 for enhanced features including 4 mm nodule detection and automated lung density analysis, and a separate clearance for InferCare RECIST for standardized tumour assessment. European and UK marking covers InferRead DR Chest under MDR and UKCA, with multiple Class III NMPA registrations in China. Clearing five distinct regulatory regimes is materially harder than clearing one, and the iterative US clearances show ongoing maintenance rather than a legacy authorization.

No governance framework, monitoring commitment, or subgroup performance analysis was located. The gap is worth pressing given the deployment profile: a model trained substantially on Chinese patient populations and deployed for tuberculosis screening in Central Asia and Africa spans very different populations, and no evidence of performance consistency across them was published.

Integration into the image review workflow is emphasised as a core design priority alongside speed and accuracy, and the product is described as workflow friendly and integrating with existing review processes. Deployment across more than 380 sites in multiple countries, plus a partnership with a large US outpatient imaging provider and UN procured deployments, indicates the integration generalises across varied PACS environments rather than requiring bespoke work. No published connector list or API documentation was located. Radiology workflow integration; no EHR integration claimed.

No hosting, tenancy, or data residency terms were located. This matters more than usual here, since a China headquartered vendor processing US and European patient imaging raises cross border data questions that procurement will need answered and the vendor does not address publicly.

No rates are published, though the company has stated it offers the system under a number of pricing options rather than a single model, which at least signals flexibility. UN procurement for tuberculosis screening deployments implies the product can be bought through public tender processes, which typically involve competitive pricing disclosure to the purchaser even where rates are not public. Nothing on per study, per site, or licensing cost was located.

The widest coverage in this index's imaging lane, spanning three distinct clinical functions rather than one. Diagnostic detection covers lung CT, chest radiography, and coronary CTA. Surgical planning covers thorax, liver, and urology, a domain almost no imaging AI competitor addresses. Oncology response assessment is covered by InferCare RECIST. Settings span diagnostic radiology, lung cancer screening programmes, surgical planning, oncology follow up, and public health tuberculosis screening in low resource countries. That last dimension, functioning in UN procured screening programmes in Kyrgyzstan and Zimbabwe, extends relevance well beyond the western hospital market most indexed competitors serve.